Testing to no avail? the diagnostic and treatment conundrum in patients with extraesophageal manifestations of gastroesophageal reflux disease

Extraesophageal reflux (EER), which includes cough, asthma, and laryngopharyngeal reflux (LPR), is an important and prevalent disease state with a large economic burden of up to fifty billion dollars, largely due to the pharmaceutical costs of empiric treatment (1).